Back to Search Start Over

Clinical, Immunologic and Molecular Spectrum of Patients with Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome: A Systematic Review

Authors :
Afshin Shirkani
Farhad Jadidi-Niaragh
Nasim Hafezi
Majid Zaki-Dizaji
Amir Almasi-Hashiani
Hassan Abolhassani
Zeineb Zian
Gholamreza Azizi
Araz Sabzevari
Haleh Hamedifar
Fatemeh Kiaee
Mahdi Goudarzvand
Fatemeh Aghamahdi
Reza Yazdani
Asghar Aghamohammadi
Source :
Endocrine, metabolicimmune disorders drug targets. 21(4)
Publication Year :
2020

Abstract

Background: Immunodeficiency, centromeric instability and facial dysmorphism (ICF) syndrome is a rare autosomal recessive immune disorder presenting with hypogammaglobulinemia, developmental delay, and facial anomalies. The ICF type 1, type 2, type 3 and type 4 are characterized by mutations in DNMT3B, ZBTB24, CDCA7 or HELLS gene, respectively. This study aimed to present a comprehensive description of the clinical, immunologic and genetic features of patients with ICF syndrome. Methods: PubMed, Web of Science, and Scopus were searched systemically to find eligible studies. Results: Forty-eight studies with 118 ICF patients who met the inclusion criteria were included in our study. Among these patients, 60% reported with ICF-1, 30% with ICF-2, 4% with ICF-3, and 6% with ICF-4. The four most common symptoms reported in patients with ICF syndrome were: delay in motor development, low birth weight, chronic infections, and diarrhea. Intellectual disability and preterm birth among patients with ICF-2 and failure to thrive, sepsis and fungal infections among patients with ICF-1 were also more frequent. Moreover, the median levels of all three immunoglobulins (IgA, IgG, IgM) were markedly reduced within four types of ICF syndrome. Conclusion: The frequency of diagnosed patients with ICF syndrome has increased. Early diagnosis of ICF is important since immunoglobulin supplementation or allogeneic stem cell transplantation can improve the disease-free survival rate.

Details

ISSN :
22123873
Volume :
21
Issue :
4
Database :
OpenAIRE
Journal :
Endocrine, metabolicimmune disorders drug targets
Accession number :
edsair.doi.dedup.....4917f72a7d5ee8495a49879ca4e3051d